The FDA made two moves on compounded GLP-1s this month, and I can already guess how a lot of weight-loss and wellness clinics are reading them: “that’s a pharmacy problem, my compounder will figure it out.”

Bro. It’s your problem too. Let me show you why, and then let me hand you the actual list of words to pull off your website.

What happened

Two things, close together.

One: the FDA proposed to permanently leave semaglutide, tirzepatide, and liraglutide OFF the 503B “bulks list,” saying it found no clinical need for outsourcing facilities to compound them from bulk drug substance. The public comment window closes Monday, June 29, 2026.

Two: the FDA sent out another wave of warning letters to telehealth companies over how they market compounded GLP-1s, calling the claims misbranding under the Food, Drug, and Cosmetic Act. This is the third batch in under a year (roughly 80 letters the prior fall, about 30 in the spring, and the newest round this month). The agency also published two compliance pages: one for telehealth companies promoting compounded drugs, and one on its concerns with compounded GLP-1s.

The pincer

Read those together. The first move chokes the cheap supply. The second goes after the marketing. And the marketing arm points straight at clinics, not just pharmacies.

The marketing rule that actually catches clinics: “net impression”

Here’s the legal framework, because it’s the part that turns “be careful with your ads” into something you can act on.

FDA evaluates your marketing under a doctrine called misleading net impression (FDCA Section 502(a)). The test isn’t whether any single sentence is false. It’s whether your website, branding, and promotions, taken as a whole, could leave a consumer believing your compounded product is FDA-approved, FDA-reviewed, or equivalent to the brand-name drug. Under that standard, a statement can be 100% technically true and still make your product “misbranded” if the overall picture misleads.

That’s why “the compounder handles the product, I just run the program” doesn’t save you. The net impression of your funnel, your landing page, your before-and-afters, your pricing, is what FDA reads.

The exact phrases FDA is flagging

This is the part to take to your website today. FDA’s letters and its new page call out specific moves. Pull these:

• Calling it a “generic” version of Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded drugs are not FDA-approved generics.
• Any claim, express or implied, that FDA approved, reviewed, or evaluated the compounded product.
• “Clinically proven” or equivalence language, anything implying it performs the same as the branded drug.
• “FDA-approved pharmacy” or “FDA-licensed facility.” FDA does not approve or license compounders that way, so the phrase itself is treated as misleading.
• “Same active ingredient as [brand]” used in a way that implies sameness with the approved drug.
• Branding or labeling that makes it look like you are the compounder when you’re not.

Read FDA’s own two pages (linked above). They’re short, and they’re essentially the agency telling you what it will cite you for.

The legal read: 503B is not 503A

One distinction most “it’s just the pharmacy” takes get wrong. The bulks-list proposal is about 503B outsourcing facilities that mass-produce without a patient-specific prescription. It does not, by itself, end 503A patient-specific compounding, where a pharmacy fills a script for one named patient.

But don’t exhale. The branded shortage that made mass GLP-1 compounding legal is over. Without the shortage and without a 503B bulks pathway, the legal room keeps narrowing toward genuine 503A patient-specific need: a documented clinical reason a particular patient needs a compounded version, like an allergy to an inactive ingredient or a dose the manufacturer doesn’t make. “It’s cheaper” is not that reason.

This isn’t only a marketing problem

FDA’s GLP-1 page makes clear it sees real safety and supply risk, not just bad ads:

• More than 1,700 adverse events tied to compounded semaglutide and tirzepatide as of May 21, 2026.
• FDA’s position that retatrutide and cagrilintide may not be used in compounding at all. If either is on your menu, that’s a today problem.
• Import alerts aimed at keeping poor-quality GLP-1 active ingredients out of the country, plus counterfeit brand-name GLP-1s circulating.

If you can’t say where your product and its active ingredient actually come from, that’s its own exposure.

Now make it about you

If your weight-loss program runs on a steady supply of compounded semaglutide or tirzepatide, you’re exposed on two fronts: the cheap bulk supply is closing, and your marketing is exactly what FDA just put another batch of companies on notice for. “The compounder got the letter, not me” is not the shield you want. Your name is on the program, the funnel, and the ads.

What to do with this

• Scrub your site against the list above, then read FDA’s two pages and fix anything that matches.
• Judge your whole funnel by net impression, not sentence by sentence. Would a consumer think this is FDA-approved? If maybe, fix it.
• Audit your supply chain: 503B facility or 503A patient-specific pharmacy, where the active ingredient sources from, and whether anything on your menu (retatrutide, cagrilintide) is a no-go.
• Build a real medical-necessity standard for any compounded GLP-1. Cost and convenience are not clinical need.
• Have a branded-transition plan so a finalized rule doesn’t strand patients mid-program.
• If you want a voice in the rule, comment by Monday, June 29. After that, you’re reacting.

The headline is a proposed rule and another batch of letters. The lesson is that compounded GLP-1s have moved from “easy revenue line” to “thing you’d better be able to defend,” in your supply chain and on every page of your website.

Real compliance strategy from a real attorney.

Y’all stay protected out there.

---

Want the plain-English framework for building a defensible weight-loss and compounding workflow, and a marketing review that survives the net-impression test? That’s exactly what we do inside The Protected Practice.

Court Approved Council is owned by Court Approved, PLLC and is not a law firm. Nothing here is legal advice and no attorney-client relationship is formed.